Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Ernexa Therapeutics Inc. entered into Exclusive License Agreement with Factor Bioscience Limited valued at 20% of Sublicense Fees before Expiration Date, 30% during Renewal Term; at least $100 million in sub (effective 2023-02-20).
- Action
- entry
- Agreement
- license
- Counterparty
- Factor Bioscience Limited
- Value
- 20% of Sublicense Fees before Expiration Date, 30% during Renewal Term; at least $100 million in sub
- Effective
- 2023-02-20
Exact text from the filing
On February 20, 2023, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into an exclusive license agreement (the “ Exclusive License Agreement ”) with Factor Bioscience Limited (“ Factor ”)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Ernexa Therapeutics Inc. terminated Amended Factor License Agreement with Factor valued at Terminated and superseded by Exclusive License Agreement (effective 2023-02-20).
- Action
- termination
- Agreement
- license
- Counterparty
- Factor
- Value
- Terminated and superseded by Exclusive License Agreement
- Effective
- 2023-02-20
Exact text from the filing
Effective on February 20, 2023, the Exclusive License Agreement terminated and superseded the Amended Factor License Agreement.
View on SEC.gov